Bjørn Sperling

1.2k total citations
34 papers, 760 citations indexed

About

Bjørn Sperling is a scholar working on Pathology and Forensic Medicine, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Bjørn Sperling has authored 34 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 16 papers in Psychiatry and Mental health and 7 papers in Physiology. Recurrent topics in Bjørn Sperling's work include Migraine and Headache Studies (15 papers), Multiple Sclerosis Research Studies (9 papers) and Trigeminal Neuralgia and Treatments (8 papers). Bjørn Sperling is often cited by papers focused on Migraine and Headache Studies (15 papers), Multiple Sclerosis Research Studies (9 papers) and Trigeminal Neuralgia and Treatments (8 papers). Bjørn Sperling collaborates with scholars based in Denmark, United States and United Kingdom. Bjørn Sperling's co-authors include Niels A. Lassen, Jyoji Nakagawara, Cornelius Weiller, Julio Herrero García, Mette Krog Josiassen, Anders Ettrup, Messoud Ashina, Patricia Pozo‐Rosich, Michel Lantéri‐Minet and Roger Cady and has published in prestigious journals such as Neurology, Stroke and The Lancet Neurology.

In The Last Decade

Bjørn Sperling

32 papers receiving 741 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bjørn Sperling Denmark	14	287	269	194	142	122	34	760
Marjan Zaletel Slovenia	19	71 0.2×	204 0.8×	221 1.1×	144 1.0×	87 0.7×	53	793
Charlotte Madsen Denmark	16	237 0.8×	157 0.6×	181 0.9×	143 1.0×	142 1.2×	40	926
I Christiansen Denmark	16	249 0.9×	404 1.5×	231 1.2×	43 0.3×	76 0.6×	46	1.0k
Andrea Rigamonti Italy	16	127 0.4×	280 1.0×	345 1.8×	113 0.8×	29 0.2×	59	736
Xu Yang China	17	166 0.6×	76 0.3×	90 0.5×	139 1.0×	80 0.7×	108	1.1k
G. Bogliun Italy	24	89 0.3×	660 2.5×	425 2.2×	105 0.7×	72 0.6×	54	1.7k
G. Ferlin Italy	18	142 0.5×	182 0.7×	264 1.4×	219 1.5×	350 2.9×	53	1.2k
Dimitri Renard France	18	114 0.4×	122 0.5×	519 2.7×	219 1.5×	58 0.5×	147	1.1k
Nilda Turgut Türkiye	16	66 0.2×	207 0.8×	159 0.8×	94 0.7×	35 0.3×	34	649

Countries citing papers authored by Bjørn Sperling

Since Specialization

Citations

This map shows the geographic impact of Bjørn Sperling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bjørn Sperling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bjørn Sperling more than expected).

Fields of papers citing papers by Bjørn Sperling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bjørn Sperling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bjørn Sperling. The network helps show where Bjørn Sperling may publish in the future.

Co-authorship network of co-authors of Bjørn Sperling

This figure shows the co-authorship network connecting the top 25 collaborators of Bjørn Sperling. A scholar is included among the top collaborators of Bjørn Sperling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bjørn Sperling. Bjørn Sperling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Shengyuan, Yasuhiko Matsumori, Byung‐Kun Kim, et al.. (2025). Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial. Cephalalgia. 45(10). 2235431151–2235431151.

Tassorelli, Cristina, Peter J. Goadsby, Andrew Charles, et al.. (2025). Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial. The Lancet Neurology. 24(5). 429–440.

Schim, Jack, et al.. (2024). Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial. Headache The Journal of Head and Face Pain. 65(1). 101–112. 1 indexed citations

Pozo‐Rosich, Patricia, Messoud Ashina, Stewart J. Tepper, et al.. (2024). Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study. Neurology and Therapy. 13(2). 339–353. 3 indexed citations

Ashina, Messoud, Richard B. Lipton, Jessica Ailani, et al.. (2023). Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial. European Journal of Neurology. 31(2). e16131–e16131. 4 indexed citations

Ashina, Messoud, Stewart J. Tepper, Astrid Gendolla, et al.. (2023). Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial. The Journal of Headache and Pain. 24(1). 155–155. 12 indexed citations

Barbanti, Piero, Peter J. Goadsby, Giorgio Lambru, et al.. (2022). Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. The Journal of Headache and Pain. 23(1). 153–153. 12 indexed citations

Ashina, Messoud, Michel Lantéri‐Minet, Patricia Pozo‐Rosich, et al.. (2022). Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurology. 21(7). 597–607. 78 indexed citations

Smith, Timothy R., Egilius L.H. Spierings, Roger Cady, et al.. (2021). Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. The Journal of Headache and Pain. 22(1). 16–16. 34 indexed citations

10.

Tolley, Keith, Michael Hutchinson, Andrew R. Pachner, et al.. (2014). Systematic Literature Review and Network Meta-Analysis of Pegylated Interferon Beta-1a and Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis (P7.234). Neurology. 82(10_supplement). 1 indexed citations

11.

Hupperts, Raymond, V. Becker, Claudio Gobbi, et al.. (2014). Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opinion on Drug Delivery. 12(1). 15–25. 19 indexed citations

12.

Kieseier, Bernd C., Thomas F. Scott, Scott D. Newsome, et al.. (2014). Peginterferon Beta-1a May Improve Recovery Following Relapses: Data from the Pivotal Phase 3 ADVANCE Study in Patients with Relapsing-Remitting Multiple Sclerosis (S4.003). Neurology. 82(10_supplement). 1 indexed citations

13.

Calabresi, Peter A., Shifang Liu, Ali Seddighzadeh, et al.. (2013). Safety, Tolerability and Patient Evaluation of Peginterferon beta-1a Administered Via a Single-Use Autoinjector in Relapsing Multiple Sclerosis: Data from the Phase 3 ATTAIN Study (P01.167). Neurology. 80(7_supplement). 1 indexed citations

14.

Ravnborg, Mads, Per Soelberg Sørensen, Magnus Andersson, et al.. (2010). Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. The Lancet Neurology. 9(7). 672–680. 58 indexed citations

15.

Abildstrøm, Hanne, Peter Høgh, Bjørn Sperling, et al.. (2002). Cerebral blood flow and cognitive dysfunction after coronary surgery. The Annals of Thoracic Surgery. 73(4). 1174–1178. 21 indexed citations

16.

Strauss, Gitte Irene, Kirsten Møller, Søren Holm, et al.. (2001). Transcranial doppler sonography and internal jugular bulb saturation during hyperventilation in patients with fulminant hepatic failure. Liver Transplantation. 7(4). 352–358. 25 indexed citations

17.

Gideon, Peter, Sverre Rosenbaum, Bjørn Sperling, & Palle Petersen. (1999). MR-visible brain water content in human acute stroke. Magnetic Resonance Imaging. 17(2). 301–304. 13 indexed citations

18.

García, Julio Herrero, Niels A. Lassen, Cornelius Weiller, Bjørn Sperling, & Jyoji Nakagawara. (1996). Ischemic Stroke and Incomplete Infarction. Stroke. 27(4). 761–765. 167 indexed citations

19.

Henriksen, Ole, Peter Gideon, Bjørn Sperling, et al.. (1992). Cerebral lactate production and blood flow in acute stroke. Journal of Magnetic Resonance Imaging. 2(5). 511–517. 34 indexed citations

20.

Friberg, Lars, Jes Olesen, Helle K. Iversen, & Bjørn Sperling. (1991). Dilatation of the Middle Cerebral Artery: A Mechanism of Migraine Pain and its Reversal by I.V. Injection of a 5-HT₁Like Receptor Agonist (Sumatriptan).. Cephalalgia. 11(11_suppl). 7–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact